Bladder 2023-06-26T09:40:08+00:00 Editorial Office of Bladder Open Journal Systems <p>The <em>Bladder</em> (ISSN 2327-2120) is an open-access journal committed to publishing peer-reviewed papers on cutting-edge and innovative research on bladder biology and disease.</p> <p>Bladder has been included by the following indexing and archiving services: PubMed Central (PMC), Google Scholar, CrossRef, OCLC, SHERPA/RoMEO and Portico.</p> <p><a href="">Read More</a></p> Advances in the bladder cancer research using 3D culture models 2022-11-22T03:57:57+00:00 Yexin Gu Ye Lu Yunqiang Xiong Xiangpeng Zhan Taobin Liu Min Tang An Xie Xiaoqiang Liu Bin Fu <p>Bladder cancer represents the most common malignancy of the urinary system, posing a significant threat to patients' life. Animal models and two-dimensional (2D) cell cultures, among other traditional models, have been used for years to study various aspects of bladder cancer. However, these methods are subject to various limitations when mimicking the tumor microenvironment <em>in vivo</em>, thus hindering the further improvement of bladder cancer treatments. Recently, three-dimensional (3D) culture models have attracted extensive attention since they overcome the shortcomings of their traditional counterparts. Most importantly, 3D culture models more accurately reproduce the tumor microenvironment in the human body because they can recapitulate the cell-cell and cell-extracellular matrix interactions. 3D culture models can thereby help us gain deeper insight into the bladder cancer. The 3D culture models of tumor cells can extend the culture duration and allow for co-culturing with different cell types. Study of patient-specific bladder cancer mutations and subtypes is made possible by the ability to preserve cells isolated from particular patients in 3D culture models. It will be feasible to develop customized treatments that target relevant signaling pathways or biomarkers. This article reviews the development, application, advantages, and limitations of traditional modeling systems and 3D culture models used in the study of bladder cancer and discusses the potential application of 3D culture models.</p> 2023-05-30T00:00:00+00:00 Copyright (c) 2023 Yexin Gu, Ye Lu, Yunqiang Xiong; Xiangpeng Zhan, Taobin Liu, Min Tang, An Xie; Xiaoqiang Liu, Bin Fu Laparoscopic and Robotic-Assisted Extended Pelvic Lymph Node Dissection for Invasive Bladder Cancer: A Review 2022-11-22T03:21:58+00:00 Weijun Fu Xu Zhang <p>Minimally invasive surgical techniques, including laparoscopic and robotic-assisted radical cystectomy (RC), are emerging as the preferred treatment options for invasive bladder cancer. Mounting evidence has demonstrated that laparoscopic and robotic-assisted RC with extended pelvic lymph node dissection (PLND) is a viable alternative for managing invasive bladder cancer. In this review, we summarized recent advances and critically assessed the minimally invasive approaches and risk factors associated with extended PLND in patients undergoing laparoscopic or robotic-assisted RC. The findings indicated that laparoscopic and robotic-assisted PLND, employing either a standard or extended approach, is technically feasible and offers benefits such as minimal invasiveness, superior visualization, reduced blood loss, and expedited recovery. The risk factors involved in the laparoscopic extended PLND are minimal. Clinically, laparoscopic and robotic-assisted extended PLND is significantly advantageous in that it sticks to the principles of open surgery and respects anatomical boundaries. Nevertheless, laparoscopic and robotic-assisted extended PLND is technically challenging and necessitate extended operation time. Furthermore, large-scale, prospective, multicenter trials are warranted to validate the long-term efficacy of laparoscopic and robotic-assisted extended PLND in terms of disease-specific survival.</p> 2023-05-31T00:00:00+00:00 Copyright (c) 2023 Weijun Fu, Xu Zhang How brain diseases affect the lower urinary tract function? 2022-11-03T07:58:17+00:00 Ryuji Sakakibara Tatsuya Yamamoto Noritoshi Sekido Setsu Sawai <p>This article reviewed brain mechanism of the lower urinary tract (LUT). Among autonomic nervous systems, LUT is unique in terms of afferent pathophysiology; bladder sensation is perceived soon after the storage phase and throughout the voiding phase. Within the brain, this is measured in experimental animals by the firing of single neurons and in humans by evoked potentials/functional neuroimaging. The evidence indicates that sphincter information goes up to the precentral motor cortex and other brain areas, and bladder information goes up to the insular cortex (IC)/anterior cingulate (ACG) and further to the prefrontal cortex (PFC). Another LUT-specific phenomenon is efferent pathophysiology: detrusor overactivity (exaggerated micturition reflex) occurs in brain diseases such as stroke (focal disease) and dementia with Lewy bodies (diffuse diseases, may overlap with each other). With the turning off and on of the brain-switch of micturition (at the periaqueductal gray [PAG]), there is a bladder-inhibitory PFC-IC/ACG-hypothalamus-PAG pathway, with interconnections via the PFC with a PFC-nigrostriatal D1 dopaminergic pathway and a PFC-cerebellar pathway. Brain diseases that affect these areas may cause a loss of the brain's inhibition of the micturition reflex, leading to detrusor overactivity. This has a significant clinical impact on patients and requires appropriate management.</p> 2023-01-30T00:00:00+00:00 Copyright (c) 2023 Ryuji Sakakibara, Tatsuya Yamamoto, Noritoshi Sekido, Setsu Sawai Should continuous bladder irrigation be recommended when single instillation of intravesical chemotherapy cannot be used after transurethral resection in low-risk non-muscle invasive bladder cancer? 2022-11-22T03:57:08+00:00 Joaquin Chemi Gustavo Martin Villoldo <p>Reducing the recurrence rate in patients with low-risk non-muscle invasive bladder cancer patients is a critical concern in the urologic community. The gold standard treatment is single instillation (SI) of intravesical chemotherapy after transurethral resection of bladder tumor (TURBT), but unfortunately, it is underused. Continuous bladder irrigation (CBI) after TURBT is an alternative strategy to SI for the prevention of bladder tumor implantation and recurrence. The aim of this review was to present the evidence that supports CBI after TURBT when SI is not possible.</p> 2023-03-17T00:00:00+00:00 Copyright (c) 2023 Joaquin Chemi, Gustavo Martin Villoldo Efficacy of Pentosan Polysulfate Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome 2023-06-26T09:40:08+00:00 Mehmet Gürkan Arıkan Basri Cakiroglu <p><strong>Objectives</strong>: Pentosan Polysulfate (PPS) is the only oral treatment for interstitial cystitis (IC)-bladder pain syndrome (BPS) approved by the World Health Organization. Self-evaluation scales can provide more objective results on pre- and post-treatment satisfaction. The aim of this study was to investigate the effect of pentosan polysulfate treatment on symptoms in IC-BPS patients.<br /><strong>Methods</strong>: This study included 37 adult male and female patients with IC-BPS who reported pain, urinary urgency, polyurea, and nocturia without urinary tract infection for a minimum of six months prior to the study and were taking 300 mg/day oral pentosan polysulfate. Pre- and post-treatment symptoms, Interstitial Cystitis Symptom Index (ICSI) Scores, quality of life (QoL) scores (1‒4), and satisfaction conditions were examined.<br /><strong>Results</strong>: Following the application of inclusion and exclusion criteria, mean age of 37 suitable patients was 46.0±11.9 years and 27% (10 individuals) of the patients were male. Pre-treatment, ICSI scores, and measures of satisfaction degree and QoL increased significantly after the treatment (p&lt;0.001). Adverse reaction was detected in two patients (5.4%) among the patients treated with pentosan polysulfate.<br /><strong>Conclusions</strong>: Oral pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome treatment could achieve recovery in symptoms, increase Interstitial Cystitis Symptom Index score and improve quality of life and patient satisfaction.</p> 2023-09-15T00:00:00+00:00 Copyright (c) 2023 Mehmet Gürkan Arıkan, Basri Cakiroglu The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer 2023-03-10T00:15:49+00:00 Bowen Chen Bo Shu Zhenghao Liu Junyu Zhu Chunjin Ke Xing Zeng Zhiquan Hu Chunguang Yang <p><strong>OBJECTIVE</strong>: To investigate the utility of fluorescence <em>in situ</em> hybridization (FISH) in secondary electroresection of bladder cancer. <br /><strong>METHODS</strong>: From January 2016 to April 2022, bladder cancer patients who had undergone secondary electroresection in Tongji Hospital and had preoperative urine FISH were recruited, and the positive rate, accuracy, sensitivity, specificity, genetic material changes and predictive power on malignancy degree of FISH in the secondary electroresection of bladder cancer were examined. <br /><strong>RESULTS</strong>: Twenty-six patients with bladder cancer were included in this study, and 8 were confirmed by secondary electroresection, including 6 cases positive for FISH positive and 2 negative for FISH. Besides, among the subjects, 18 were without tumor recurrence, including 1 case with positive FISH results and 17 with negative FISH results. Tumor recurrence was diagnosed in 85.71% (6/7) of FISH-positive patients in secondary electroresection while only 10.53% (2/19) of FISH-negative patients were found to develop tumor recurrence in the secondary electroresection. The sensitivity of FISH for the detection of bladder cancer before secondary electroresection was 75%, with a specificity of 94.44%, and an accuracy of 88.46%. A 6-month follow-up revealed that 2 of the 8 recurrent patients underwent radical resection of bladder cancer, and the remaining 6 patients had no recurrence, as confirmed by regular bladder perfusion and microscopy. In the 18 non-recurrent patients during secondary electroresection, no recurrence developed.<br /><strong>CONCLUSIONS</strong>: Urine FISH can achieve a high detection rate and specificity for secondary electroresection of bladder cancer. If a bladder cancer patient who are indicated for secondary electroresection is negative for urine FISH, the recurrence rate after secondary electroresection will be low, and the cystoscopy can be performed before deciding whether to perform secondary electroresection.</p> 2023-07-25T00:00:00+00:00 Copyright (c) 2023 Bowen Chen, Bo Shu, Zhenghao Liu, Junyu Zhu, Chunjin Ke, Xing Zeng, Zhiquan Hu; Chunguang Yang Bladder leiomyoma and the utility of 18F-Fluorodeoxyglucose-Positron Emission Tomography – a Case Report 2023-02-08T03:11:05+00:00 Kylie Yen-Yi Lim Kerelus Morkos Sidney M Levy Paul Davis <p>Bladder leiomyomas are rare neoplasms and various diagnostic methods are available to assist in confirming diagnosis preoperatively. Presented here is a case of bladder leiomyoma in a 41-year-old female who presented with urinary symptoms and right thigh pain. Imaging revealed a soft tissue density mass in the bladder wall. However concerns of a leiomyosarcoma remained. An <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) demonstrated low FDG uptake and absence of metastatic lesions. In combination with operative findings, the tumor allowed for localized resection instead of more invasive partial cystectomy. Therefore, FDG-PET might be used to support the diagnosis of leiomyoma and potentially facilitate a less aggressive surgical management.</p> 2023-05-04T00:00:00+00:00 Copyright (c) 2023 Kylie Yen-Yi Lim, Kerelus Morkos, Sidney M Levy, Paul Davis